Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Know Your Investor: Perceptive Advisors (March’25 Edition)
Shots:   The March edition highlights Perceptive Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and life sciences sectors In 2024, Perceptive Advisors invested approximately $5.81B in 44 companies through six funding rounds, including private and debt financing For the complete report, reach out to us at connect@pharmashots.com  With…
March 20, 2025
EMA Marketing Authorization of New Drugs in February 2025
EMA Marketing Authorization of New Drugs in February 2025
Shots:    The EMA’s CHMP has granted positive opinions and approvals to 5 Biologics and 2 New Chemical Entities in February 2025, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Merck’s Welireg to treat Von Hippel-Lindau & Renal Cell Carcinoma    PharmaShots has compiled a list of 6 drugs…
March 18, 2025
The US FDA New Drug Approvals in February 2025
The US FDA New Drug Approvals in February 2025
Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of February 2025       The US FDA has approved a total of 3 new drug including 3 new molecular entities and leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was Abbvie’s Emblaveo securing approval for…
March 11, 2025
A Complete Account of EMA Approvals in 2024
A Complete Account of EMA Approvals in 2024
Shots:   In 2024, EMA approved around 53 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, vaccines, diagnostic agents, pneumology, nephrology, hepatology, ophthalmology, and endocrinology   PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, &…
March 6, 2025
Key Biosimilars Events of February 2025
Key Biosimilars Events of February 2025
Shots:        Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency         Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients         A major highlight was the Samsung Bioepis & Teva Partners to Commercialize…
March 4, 2025
New Drug Designations - January 2025
New Drug Designations – January 2025
Shots:    PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA  The January 2025 report covers designations granted to 53 drugs and 9 medical devices, spanning 18 small molecules, 13 biologics, 13 cell and gene therapies & 9 medical devices among…
February 28, 2025
Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)
Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)
Shots:  Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that leads to the progressive degeneration of nerve cells in the spinal cord and brain  Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry…
February 25, 2025
EMA Marketing Authorization of New Drugs in January 2025
EMA Marketing Authorization of New Drugs in January 2025
Shots:    The EMA’s CHMP has granted positive opinions to 5 Biologics in January 2025, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were Merck’s Capvaxive to treat Pneumococcal Disease  PharmaShots has compiled a list of 4 drugs that have been granted positive opinions and approvals by the EMA’s…
February 18, 2025
The US FDA New Drug Approvals in January 2025
The US FDA New Drug Approvals in January 2025
Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of January 2025       The US FDA has approved a total of 3 new drug including 2 new molecular entities and 1 biologic leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was Daiichi Sankyo &…
February 11, 2025
Know Your Investor: Orbimed (February’ 25 Edition)
Know Your Investor: Orbimed (February’ 25 Edition)
Shots:    The February edition highlights OrbiMed Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and biotech sectors  In 2024, OrbiMed expanded its portfolio by adding 49 companies, investing approximately $6.08B across five funding rounds, including private and debt financing  For the complete report, contact us at connect@pharmashots.com  OrbiMed primarily…
February 6, 2025
Load more